Search Within

Sujata Patil

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (70)
  2. Journal Article (55)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Biostatistics Service (127)
  2. Department of Medicine (127)
  3. Epidemiology and Biostatistics (127)
  4. Population Sciences Research Program (127)
  5. Solid Tumor Oncology Division (126)
  6. Survivorship Research (106)

More Groups

People
  1. Clifford Hudis (44)
  2. Shari Goldfarb (34)
  3. Mark Robson (32)
  4. Chau Dang (30)
  5. Larry Norton (29)
  6. Shanu Modi (25)

More People

Years
  1. 2023 (2)
  2. 2022 (6)
  3. 2021 (10)
  4. 2020 (17)
  5. 2019 (14)
  6. 2018 (10)

More Years

Publications
  1. Journal of Clinical Oncology (44)
  2. Cancer Research (18)
  3. Breast Cancer Research and Treatment (9)
  4. Cancer (7)
  5. The Oncologist (5)
  6. Annals of Surgical Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (45)
  2. American Association for Cancer Research (22)
  3. Springer (13)
  4. Elsevier Inc. (10)
  5. Wiley Blackwell (8)
  6. Oxford University Press (5)

More Publishers

Results (127)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ethnic disparities in the impact of breast cancer on the workforce: A pilot study
    Meeting Abstract

    Blinder, V. S.; Eberle, C. E.; Patil, S.; Ramirez, J.; McNish, T.; Min, S. H.; Bhagwati, N.; Lee, S.; Hudis, C. A.; Oeffinger, K. C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center
    Meeting Abstract

    Fontes Santos De Teive Argolo, D.; Smyth, L. M.; Iyengar, N. M.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A prospective longitudinal study of the impact of breast cancer treatment with adjuvant chemotherapy or tamoxifen alone on ovarian reserve
    Meeting Abstract

    Goldfarb, S. B.; Bedoschi, G.; Grunblatt, E.; Goswami, S.; Cigler, T.; Quistorff, J.; Pacheco, F.; Stobezki, R.; Robson, M.; Moy, F.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Poly(ADP-ribose) polymerase (PARP) inhibitors for locally advanced or metastatic breast cancer
    Journal Article

    Khasraw, M.; Patil, S. M.; Traina, T. A.; Robson, M. E.
    Cochrane Database of Systematic Reviews (2014)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A Prospective Longitudinal Study of the Impact of Breast Cancer Chemotherapy on Ovarian Reserve: Do Individuals Have Differing Susceptibilities?
    Meeting Abstract

    Oktay, K.; Goldfarb, S.; Bedoschi, G.; Quistorff, J.; Grunblatt, E.; Cigler, T.; Moy, F.; Patil, S.; Goswami, S.; Dickler, M.
    Fertility and Sterility (2014)

    Fulltext@MSK | Save